By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – AB Sciex and Alturas Analytics today announced a deal combining technologies from both firms to drive adoption of dried blood spot analysis for drug discovery and development.

Under the terms of the deal, Alturas scientists will use AB Sciex's QTrap 5500 mass spectrometry platform and novel microflow chromatography technology from AB Sciex's Eksigent business to build out workflows for dried blood spot analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.